Lexaria Announces 2023 Annual Meeting Results
Lexaria Announces 2023 Annual Meeting Results
Source: pr-inside.com
📰 Lexaria Bioscience News
Page 9 - Lexaria Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lexaria Bioscience. Real-time updates on events, politics, business and more.
Lexaria Bioscience Corp.: Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the pricing of
Source: finanznachrichten.de
Why Is Nikola (NKLA) Stock Down Today?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nikola (NASDAQ:NKLA) stock is taking a beating on Tuesday after the company ann...
Source: businessinsider.com
Why Is Lexaria Bioscience (LEXX) Stock Down 27% Today?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lexaria Bioscience (LEXX) stock is falling on Tuesday after the company revealed details about…
Source: biztoc.com
Lexaria Bioscience Corp.: Lexaria's Human Clinical Nicotine Study Completes Dosing as Planned
KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that dosing of the targeted
George Jurcic Exchange Commission Lexaria Bioscience Corp View Company Or Lexaria Drug Administration Lexaria Bioscience Corp
Source: finanznachrichten.de
Lexaria's Human Clinical Nicotine Study Completes Dosing as Planned 2023-05-08
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
Lexaria Bioscience Corp News Network Drug Administration Company Or Lexaria Lexaria Bioscience Plasma Levels
Source: pr-inside.com
Short Interest in Lexaria Bioscience Corp. (NASDAQ:LEXX) Drops By 6.1%
Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Rating) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 317,900 shares, a decline of 6.1% from the March 31st total of 338,500 shares. Based on an average daily volume of 20,800 shares, the […]
Lexaria Bioscience Susquehanna International Group Renaissance Technologies Lexaria Bioscience Corp Dimensional Fund Advisors Virtu Financial
Source: theenterpriseleader.com
Lexaria Bioscience : Corporate Highlight Sheet
LEXARIA BIOSCIENCE CORP. NASDAQ: LEXX INVESTOR CONTACT Phone: 250-765-6424 ext. 202... | May 1, 2023
Source: marketscreener.com
Lexaria Bioscience Corp.: Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
Clinical study will evaluate safety and tolerability of Lexaria's patented DehydraTECH-CBD as a potential treatment for hypertensionCalifornia-based InClin to provide CRO services to manage and expedite
New South Wales George Jurcic Contract Research Organization Exchange Commission Company Or Lexaria Lexaria Bioscience Corp
Source: finanznachrichten.de
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension ...
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension ...
New South Wales News Network Company Or Lexaria Inclin Inc Contract Research Organization Drug Administration
Source: pr-inside.com